Maintenance treatment in bipolar disorder: a focus on aripiprazole

References

• McIntyre RS, Konarski JZ. Bipolar disorder: a national health concern. CNS Spectr.9(11 Suppl. 12), 6–15 (2004).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Vornik LA. Bipolar disorder – costs and comorbidity. Am. J. Manag. Care11(Suppl. 3), S85–S90 (2005).
   Web of Science ®Google Scholar
• Kessler RC, Akiskal HS, Ames M et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry163(9), 1561–1568 (2006).
   PubMed Web of Science ®Google Scholar
• Begley CE, Annegers JF, Swann AC et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics19(5 Pt 1), 483–495 (2001).
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry64(12), 1465–1475 (2003).
   PubMed Web of Science ®Google Scholar
• Osby U, Brandt L, Correia N et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry58(9), 844–850 (2001).
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O’Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord.7(Suppl. 3), 5–69 (2005).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic–depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry2, 161–174 (2003).
   Google Scholar
• Smith DJ, Harrison N, Muir W et al. The high prevalence of bipolar spectrum disorders in young adults with recurrent depression: toward an innovative diagnostic framework. J. Affect. Disord.84(2–3), 167–178 (2005).
   PubMed Web of Science ®Google Scholar
• Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol. Psychiatry6, 558–572 (2000).
   Google Scholar
• Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry66(7), 870–886 (2005).
   PubMed Web of Science ®Google Scholar
• Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the systematic treatment enhancement program. Arch. Gen. Psychiatry64(4), 419–426 (2007).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, Parikh S et al. Lithium revisited. Can. J. Psychiatry46(4), 322–327 (2001).
   PubMed Web of Science ®Google Scholar
• Grof P. Has the effectiveness of lithium changed? Impact of the variety of lithium’s effects. Neuropsychopharmacology19(3), 183–188 (1998).
   PubMed Web of Science ®Google Scholar
• Bauer MS, Mitchner L. What is a “mood stabilizer”? An evidence-based response. Am. J. Psychiatry161(1), 3–18 (2004).
   PubMed Web of Science ®Google Scholar
• Maj M, Pirozzi R, Magliano L et al. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am. J. Psychiatry160(12), 2134–2140 (2003).
   PubMed Web of Science ®Google Scholar
• Chou JC, Fazzio L. Maintenance treatment of bipolar disorder: applying research to clinical practice. J. Psychiatr. Pract.12(5), 283–299 (2006).
   PubMedGoogle Scholar
• Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr.11(6), 465–471 (2006).
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry54(1), 37–42 (1997).
   PubMed Web of Science ®Google Scholar
• Geddes JR, Burgess S, Hawton K et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry161(2), 217–222 (2004).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Tohen M, Narendran R et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J. Clin. Psychiatry60(4), 232–236 (1999).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE Jr, Pope HG Jr et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J. Clin. Psychopharmacol.12(Suppl. 1), S42–S52 (1992).
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry159(Suppl. 4), 1–50 (2002).
   Web of Science ®Google Scholar
• Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology28(7), 1374–1382 (2003).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry57(5), 481–489 (2000).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, McCann S et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord.5(1), 28–35 (2003).
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen LS, Stuppes T et al. Polycystic ovarian syndrome is associated with valproate use in bipolar women. Presented at: American Psychiatric Association 154th Annual Conference. New York, NY, USA, 1–6 May 2004.
   Google Scholar
• Joffe H, Cohen LS, Suppes T et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol. Psychiatry60(12), 1378–1381 (2006).
   PubMed Web of Science ®Google Scholar
• O’Donovan C, Kusumakar V, Graves GR et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J. Clin. Psychiatry63(4), 322–330 (2002).
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry59(11), 1078–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry65(3), 432–441 (2004).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry64(9), 1013–1024 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry60(2), 79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry63(10), 1069–1072 (2006).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry66(3), 28–36 (2005).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Citrome L. Latest therapies for bipolar disorder. Looking beyond lithium. Postgrad. Med.117(2), 25–32, 35 (2005).
   PubMed Web of Science ®Google Scholar
• Dando S, Tohen M. Olanzapine – relapse prevention following mania. J. Psychopharmacol.20(Suppl. 2), 31–38 (2006).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am. J. Psychiatry161(1), 169–171 (2004).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry66(Suppl. 3), 28–36 (2005).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatry62(12), 923–924 (2001).
   PubMed Web of Science ®Google Scholar
• Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann. Pharmacother.37(5), 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO et al. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin. Pharmacother.8(7), 1001–1009 (2007).
   PubMed Web of Science ®Google Scholar
• Aihara K, Shimada J, Miwa T et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res.1003(1–2), 9–17 (2004).
   PubMed Web of Science ®Google Scholar
• Tadori Y, Miwa T, Tottori K et al. Aripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol.515(1–3), 10–19 (2005).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry67(4), 626–637 (2006).
   PubMed Web of Science ®Google Scholar
• Wood MD, Scott C, Clarke K et al. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur. J. Pharmacol.546(1–3), 88–94 (2006).
   PubMed Web of Science ®Google Scholar
• Chessick CA, Allen MH, Thase M et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev.3, CD006115 (2006).
   Google Scholar
• Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry67(4), 626–637 (2006).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry60(4), 392–400 (2003).
   PubMed Web of Science ®Google Scholar
• Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry163(2), 247–256 (2006).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry60(3), 261–269 (2003).
   PubMed Web of Science ®Google Scholar
• Judd LL, Schettler PJ, Akiskal HS et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. J. Neuropsychopharmacol.6(2), 127–137 (2003).
   PubMed Web of Science ®Google Scholar
• McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J. Clin. Psychiatry63(Suppl. 3), 15–20 (2002).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Wilkins K et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can. J. Psychiatry51, 274–280 (2006).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Misener VL et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann. Clin. Psychiatry17(2), 83–93 (2005).
   PubMedGoogle Scholar
• Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J. Clin. Psychiatry60(Suppl. 2), 77–84 (1999).
   PubMed Web of Science ®Google Scholar
• Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry162, 1281–1290 (2005).
   Google Scholar
• Ketter TA, Wang PW, Chandler RA et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann. Clin. Psychiatry18(3), 169–172 (2006).
   PubMedGoogle Scholar
• Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J. Med. Invest.52(Suppl.), 284–290 (2005).
   PubMedGoogle Scholar